Skip to main content
. Author manuscript; available in PMC: 2008 Aug 20.
Published in final edited form as: J Cardiovasc Electrophysiol. 2006 Nov;17(11):1230–1238. doi: 10.1111/j.1540-8167.2006.00592.x

Figure 5. Influence of pre-CS beta-blocker therapy on post-CS AF and pre-CS atrial refractory period.

Figure 5

A, Comparison of incidence of post (3 day)-CS AF between patients not treated (Inline graphic, −BB, n=13/48) and treated (Inline graphic, +BB, n=13/99), respectively, for >7 days pre-CS with a beta-blocker. Asterisk denotes P<0.05 between groups. B, Comparison of magnitude of increase in mean pre-CS atrial cellular effective refractory period (ERP) associated with pre-CS treatment (>7 days) of patients with a beta-blocker, between those in post-CS sinus rhythm (□; patient n: −BB=21; +BB=43) and post (3 day)-CS AF (■; patient n: −BB=4; +BB=5). †s denote P<0.05 for the increase in ERP associated with pre-CS β-blockade within each group.